PH:(08) 9420 4900

FAX:(08) 9386 9277

Phone

Deep Brain Stimulation Information Session

Please join us for a presentation by the Perth DBS team on recent advances in Deep Brain Stimulation for Parkinson’s disease, Essential Tremor and Dystonia

For patients and families Deep Brain Stimulation Information Session

Saturday 21st September 2019 10am – 12 noon

Seminar location: The University club Entrance 1, Hackett Dr, Crawley WA 6009

Talks will cover:

  • How DBS is performed
  • Patient selection and outcomes
  • Living with DBS

PLACES ARE LIMITED PLEASE RSVP

Our friends in QLD have completed their 1000th DBS case!

Click here for flyer

Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults

Abstract

Background: OnabotulinumtoxinA (BOTOX®, Allergan plc, Dublin, Ireland) is approved for the preventive treatment of headaches in adult patients with chronic migraine (CM) in Australia by the country’s reimbursement mechanism for medicines, the Pharmaceutical Benefits Scheme (PBS). To our knowledge, this study represents the first focused report evaluating real-world evidence of onabotulinumtoxinA treatment via the PBS in Australian clinics.

Methods: This study reviewed the medical records of adults with inadequately controlled CM from 7 private neurology practices in Australia who, beginning in March 2014, received PBS-subsidized onabotulinumtoxinA per product labelling for the first time. The primary effectiveness measure was the percentage of patients achieving a response defined by 50% or greater reduction in headache days from baseline after 2 treatment cycles. Additional data were recorded in the case report form when available and included demographics, clinical characteristics, headache severity and frequency, Headache Impact Test (HIT-6) score, medication use, and days missed of work or study at baseline, after 2 treatment cycles, and at last follow-up. Differences in mean changes from baseline were evaluated with a 1-tailed t-test or Pearson’s chi-squared test (p < 0.05).

Results: The study population included 211 patients with a mean (SD) of 25.2 (5.3) monthly headache days at baseline. In the primary outcome analysis, 74% of patients achieved a response, with a mean (SD) of 10.6 (7.9) headache days after 2 treatment cycles (p < 0.001). Secondary effectiveness outcomes included mean (SD) reductions in HIT-6 score of − 11.7 (9.8) and − 11.8 (12.2) after 2 treatment cycles (p < 0.001) and final follow-up (p < 0.001), respectively, and mean (SD) decreases in days per month of acute pain medication use of − 11.5 (7.6) after 2 treatment cycles (p < 0.001) and − 12.7 (8.1) at final follow-up (p < 0.001).

Conclusion: This study provides additional clinical evidence for the consistent effectiveness of onabotulinumtoxinA for the treatment of CM in Australia. This effectiveness was made evident by reductions in migraine days, severe headache days, and HIT-6 scores from baseline.

Read More

Deep Brain Stimulation Information Session For patients and families Saturday 15th June, 2019 – 10 am

Please join us for a presentation by the Perth DBS team on recent advances in Deep Brain Stimulation for Parkinson’s disease, Essential Tremor and Dystonia

Deep Brain Stimulation Information Session For patients and families Saturday 15th June, 2019 – 10 am

World Parkinson’s Day

TRUDY Drabarek is among nearly 50 Hollywood Private Hospital Parkinson’s disease patients who have undergone Deep Brain Stimulation (DBS).

The Swan View resident was diagnosed with Parkinson’s in 2003 and had the procedure last July.

Read more

Our friends in QLD have completed their 1000th DBS case!

Our friends in QLD have completed their 1000th DBS case! Dr Rodrigues regularly travels to Brisbane to work with the team there.

Since their Deep Brain Stimulation (DBS) partnership commenced back in 2002, neurologist Professor Peter Silburn AM and neurosurgeon Associate Professor Terry Coyne OAM never imagined they would reach their 1000th DBS case milestone.

Our friends in QLD have completed their 1000th DBS case!

Read more

World Parkinson’s Day (Wednesday April 11 2018)

Management of newly-diagnosed patients through to complex/advanced Parkinson’s disease as part of a multidisciplinary team at Hollywood Private Hospital. Providing the latest medical technologies including Deep Brain Stimulation for PD, Essential Tremor and Dystonia. Specialist Medicare rebates apply, medical referral required

Completing his medical degree at The University of Western Australia in 1995, Dr Julian Rodrigues has practised as a neurologist since 2004 in the field of movement disorders, primarly Parkinson’s disease.

Julian Rodrigue

Read more

Hollywood first in Australia to deliver latest advancement in Parkinson’s Disease and Essential Tremor treatment

On Monday 8 May 2017, Hollywood Private Hospital (Hollywood) became the first healthcare facility in Australia to use a new directional system to perform Deep Brain Stimulation (DBS) and more effectively reduce the symptoms of Parkinson’s Disease (PD) and Essential Tremor (ET).

PD is a progressive, degenerative neurological condition caused by incurable loss of neurons in the brain that produce dopamine. It causes trembling and stiffness in
the limbs and trunk, slowness of movements and difficulty walking.

ET is a neurological condition that causes a rhythmic trembling of the hands, head, voice, legs or trunk. It is slowly progressive and can become disabling in some patients, as well as causing embarrassment and social isolation.

DBS is known for its ability to help individuals with PD to regain dexterity and mobility,  restoring their independence. The treatment also reduces the patient’s need for medication. In ET, it suppresses tremor to the extent where people can lead normal lives again.

Using the directional system, the procedure involves mild electrical impulses which are generated by a stimulator that is implanted around the chest in a similar way to a pacemaker. The electrical stimulation travels along thin wires called leads to specific areas of the brain to target symptoms.

Neurologist, Dr Julian Rodrigues, and Neurosurgeon, Professor Stephen Lewis, performed the surgery at Hollywood. Professor Jens Volkmann from Germany and one of the world’s leading authorities on DBS, was also in attendance.

Dr Rodrigues said “We previously weren’t able to deliver precise electrical signals through DBS. By using the new directional system to steer the current we can provide a more personalised therapy and can redirect the current post operatively as patients’ symptoms develop.”

“The treatment is far more targeted and side effects caused by unwanted stimulation to neighbouring brain areas can be avoided. I’m looking forward to seeing the positive impact it will have on patients’ quality of life.”

Hollywood Chief Executive Officer, Peter Mott, added “This advancement in DBS further
enhances our reputation as one of the State’s leading providers of neurological services. Hollywood continues to invest in and deliver the latest treatments in neurology to ensure the best possible patient care and outcomes.”

Hollywood was the first private hospital in Western Australia to offer DBS. It was also the first facility in Australia to use DBS in conjunction with the AIRO intra-operative CT  scanner, a technology that gives surgeons greater accuracy and allows them to scan patients during surgery rather than patients having to be moved to other parts of the hospital.

Deep Brain Stimulation surgery

Dr Rodrigues and Professor Volkmann measure the patient’s responsiveness during surgery

Australian Migraine Study

In May 2017 the first study showing real world results of PREEMPT injection therapy for chronic migraine was presented at the Annual Scientific Meeting of the Australian and New Zealand Association of Neurologists.

Dr Rodrigues was proud to be the only WA Headache Specialist to take part in this multi centre study and thanks the patients who contributed essential data for this important publication.

The results confirm that  75% of patients with severe chronic migraine achieve major reductions in migraine frequency and severity with this treatment.